Clinical significance of myositis-specific autoantibodies and novel biomarkers in polymyositis/dermatomyositis-associated interstitial lung disease

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19449
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: Hozumi Hironao 浜松医科大学, 医学部附属病院, 助教 (40771457)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 間質性肺疾患 / 皮膚筋炎 / 多発性筋炎 / YKL-40 / CD163 / 筋炎特異的抗体 / プロテオーム / 間質性肺炎

Outline of Final Research Achievements

We explored novel biomarkers using bronchoalveolar lavage fluids and sera of patients with polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD). The comprehensive analysis of serum myositis-specific autoantibodies suggested that the clinical features, treatment responses, and prognoses differed depending on MSA status, and therefore, therapeutic strategy should be considered according to MSA status. The shotgun proteomics using LC-MS/MS suggested that soluble CD163 and chitinase-3-like-1 (YKL-40) molecules may be candidate biomarkers for PM/DM-ILD. The validation analysis using the patients’ sera demonstrated that the two molecules were promising biomarkers for evaluating disease severity/activity and predicting prognosis.

Free Research Field

呼吸器内科学